Bruker Corp BRKR
Deals with insiders in the proxy filed Apr 10, 2026
Proxy, Item 404Deals between BRKR and its directors, executives, owners of more than 5% or their families: a relative on the payroll, a plane the company charters from its CEO, a director's company that buys from it. SEC rules (Item 404) make the company list every such deal over $120,000 in its proxy statement.
New this year
Compared with Apr 11, 2025
Paragraphs about a deal, a person or a relative with nothing like them in the proxy filed Apr 11, 2025.
Transactions with Related Persons“During 2025, the Company made equipment sales to and purchases from Promega Corporation totaling $1,828,930 and $272,860, respectively. These sales and purchases were made in the ordinary course of business and comparable to those that would have been reached by unrelated parties in arm’s-length transactions. One of the Company’s directors, Dr. William A. Linton, is the Chairman, President, and Chief Executive Officer of Promega Corporation.”
Read it in the proxyopen_in_new
Transactions with Related Persons“During 2025, Dr. Frank H. Laukien purchased 687,500 shares of Gauss Fusion GmbH (Gauss), a majority owned subsidiary of Bruker EAS GmbH, from Bruker EAS GmbH, a wholly owned subsidiary of Bruker Corporation, for EUR 2.8 million (approximately $3.1 million). Prior to these transactions Bruker EAS GmbH owned approximately 34.38% of Gauss, and subsequent to these transactions, it did not have any equity ownership of Gauss. Bruker retains a minor equity ownership in Gauss through Research Instruments GmbH, a majority owned subsidiary of Bruker Corporation. Additionally, during 2025, Dr. Laukien entered into a convertible loan agreement for an amount of EUR 2.7 million (approximately $3.1 million) to Gauss alongside two of his immediate family members who collectively contributed an additional EUR 0.6 million (approximately $0.7 million). The result of these transactions was the deconsolidation of Gauss within the Bruker Corporation’s consolidated financial statements. These transactions, which were completed at comparable values similar to those that would have been reached with unrelated parties in arms-length transactions, were reviewed and approved by the Audit Committee.”
Read it in the proxyopen_in_new
The whole section
As filed
16 paragraphs quoted as filed
Review and Approval of Transactions with Related Persons“We have adopted a written Related-Person Transactions Policy, or the RPT Policy, that prohibits transactions involving Bruker and any related person, except in accordance with the RPT Policy. For purposes of the RPT Policy, “related persons” include (a) our executive officers, directors, director nominees, greater than 5% stockholders and any immediate family members of the foregoing and (b) any firm, academic department or other entity in which any of the foregoing persons is employed or is a partner or principal or holds a similar position or in which such person has more than a 10% beneficial ownership interest. The RPT Policy applies to (i) any transaction or series of transactions in which we are a participant and in which any related person has a direct or indirect interest, other than product or service sales or purchases entered into in the ordinary course of business involving aggregate amounts of less than $50,000 annually, and (ii) any material modification of an existing transaction.”
Read it in the proxyopen_in_new
Review and Approval of Transactions with Related Persons“Our RPT Policy provides for standing pre-approval of certain categories of transactions with related persons, including:”
Read it in the proxyopen_in_new
Review and Approval of Transactions with Related Persons“transactions involving indebtedness for ordinary business travel and expense payments and similar indebtedness transactions arising in the ordinary course of business;”
Read it in the proxyopen_in_new
Review and Approval of Transactions with Related Persons“transactions in which a related person’s interest arises solely from the ownership of a class of our equity securities and in which all holders of that class of equity securities receive proportional benefits;”
Read it in the proxyopen_in_new
Review and Approval of Transactions with Related Persons“transactions involving compensation to executive officers approved, or recommended to the Board for approval, by the Compensation Committee; and transactions involving compensation to directors for services as a director of Bruker.”
Read it in the proxyopen_in_new
Review and Approval of Transactions with Related Persons“Under our RPT Policy, any related-person transaction not in one of the preceding categories must be submitted to our Executive Vice President and Chief Financial Officer for review and approval. Related-person transactions involving amounts of $500,000 or less, and product or service sales and purchases in the ordinary course of business involving aggregate amounts of $50,000 or more annually, are subject solely to review and approval, ratification, amendment, termination or rescission by our Executive Vice President and Chief Financial Officer. Any transaction in excess of $500,000 (other than a transaction involving product or service sales or purchases in the ordinary course of business), must also be forwarded to the Audit Committee for review and approval, ratification, amendment, termination, or rescission, at the discretion of the Audit Committee.”
Read it in the proxyopen_in_new
Review and Approval of Transactions with Related Persons“In reviewing such transactions, our Executive Vice President and Chief Financial Officer and/or Audit Committee, as applicable, evaluates all material facts relating to the transaction and takes into account, among other factors deemed appropriate, the related person’s relationship to Bruker and interest in the transaction, the terms of the transaction, including its aggregate value, whether the transaction is in the best interests of Bruker, the impact on a director’s independence in the event the related person is a director, a family member of a director, or an entity in which a director is a partner, stockholder or executive officer and, if applicable, the availability of other sources of comparable products or services and whether the transaction is on terms comparable to the terms available to an unrelated third party. Neither the Executive Vice President and Chief Financial Officer nor any member of the Audit Committee may participate in the review of any transaction involving such person or any of his or her immediate family members.”
Read it in the proxyopen_in_new
Review and Approval of Transactions with Related Persons“Our Executive Vice President and Chief Financial Officer must report to the Audit Committee any approval or other action taken with respect to a related party transaction at or prior to the next Audit Committee meeting following such approval or other action. Additionally, our management must provide to the Audit Committee an annual report of any amounts paid or payable to, or received or receivable from, any related person. The Audit Committee is responsible for reviewing such reports and may make inquiries or take such actions as it deems appropriate upon consideration of all of the relevant facts and circumstances.”
Read it in the proxyopen_in_new
Transactions with Related Persons“Dr. Dirk Laukien (half-brother of Dr. Frank H. Laukien), Mr. Joerg Laukien (brother of Dr. Frank H. Laukien), and Ms. Laukien- Kleiner (the stepmother of Dr. Frank H. Laukien) are co-owners of ZeroC Project GmbH, or ZeroC, which rents one property located in Faellanden, Switzerland to Bruker BioSpin AG:”
Read it in the proxyopen_in_new
Transactions with Related Persons“Pursuant to the lease agreement dated December 17, 2020 (the “Lease Agreement”), in 2025 Bruker BioSpin AG paid $292,896 in rent to ZeroC for the property located at Taemperlistrasse 8. The Lease Agreement superseded the lease agreements dated January 1, 2009, and June 1, 2012, which were terminated as of December 31, 2020. The Lease Agreement expired on December 31, 2025 and was renewed for an additional four-year term from January 1, 2026 to December 31, 2030, under terms similar to the previous agreement.”
Read it in the proxyopen_in_new
Transactions with Related Persons“Payments under the terms of the foregoing lease were equal to the estimated fair market value of the respective rental.”
Read it in the proxyopen_in_new
Transactions with Related Persons“During 2025, the Company made equipment sales to and purchases from Promega Corporation totaling $1,828,930 and $272,860, respectively. These sales and purchases were made in the ordinary course of business and comparable to those that would have been reached by unrelated parties in arm’s-length transactions. One of the Company’s directors, Dr. William A. Linton, is the Chairman, President, and Chief Executive Officer of Promega Corporation.”
Read it in the proxyopen_in_new
Transactions with Related Persons“During 2025, Dr. Frank H. Laukien purchased 687,500 shares of Gauss Fusion GmbH (Gauss), a majority owned subsidiary of Bruker EAS GmbH, from Bruker EAS GmbH, a wholly owned subsidiary of Bruker Corporation, for EUR 2.8 million (approximately $3.1 million). Prior to these transactions Bruker EAS GmbH owned approximately 34.38% of Gauss, and subsequent to these transactions, it did not have any equity ownership of Gauss. Bruker retains a minor equity ownership in Gauss through Research Instruments GmbH, a majority owned subsidiary of Bruker Corporation. Additionally, during 2025, Dr. Laukien entered into a convertible loan agreement for an amount of EUR 2.7 million (approximately $3.1 million) to Gauss alongside two of his immediate family members who collectively contributed an additional EUR 0.6 million (approximately $0.7 million). The result of these transactions was the deconsolidation of Gauss within the Bruker Corporation’s consolidated financial statements. These transactions, which were completed at comparable values similar to those that would have been reached with unrelated parties in arms-length transactions, were reviewed and approved by the Audit Committee.”
Read it in the proxyopen_in_new
Transactions with Related Persons“During 2025, the Company made equipment sales in the ordinary course of business to Asahi Kasei Corporation totaling $155,383. These sales were contracted at comparable market rates that would have been reached by unrelated parties in arm’s length transactions. One of the Company’s directors, Mr. Richard A. Packer, is a Vice Presidential Executive Officer of Asahi Kasei Corporation.”
Read it in the proxyopen_in_new
Transactions with Related Persons“Dr. Meike Hamester, the wife of Juergen Srega, the President of Bruker CALID Group, is employed by our Bruker Daltonik GmbH subsidiary as the VP & Managing Director of Bruker Biosensors. During 2025, Dr. Meike Hamester received a total compensation of $235,148, which consisted of base pay plus bonuses and an equity award. Her compensation is consistent with our total compensation philosophy, where responsibilities and experience are considered within the overall compensation package. Dr. Meike Hamester continues to be an employee of Bruker Daltonik GmbH, and she may receive compensation and other benefits in 2026 in amounts similar to those she received in 2025.”
Read it in the proxyopen_in_new
Transactions with Related Persons“Dr. Venita Busse, the wife of Falko Busse, the President of Bruker BioSpin Group, was employed by Bruker Switzerland AG, as the Director of Group Strategy Development during 2025. During 2025, Dr. Venita Busse received total compensation of $237,112, which consisted of base pay plus bonuses and an equity award. Her 2025 compensation was consistent with our total compensation philosophy, where responsibilities and experience are considered within the overall compensation package. Dr. Venita Busse is expected to separate from the Company effective June 30, 2026. Upon such separation, Dr. Venita Busse is expected to receive total compensation of approximately $185,238 (based on USD to CHF exchange rates on April 6, 2026).”
Read it in the proxyopen_in_new
Paragraphs are compared by their words, not read by AI: one counts as new when no paragraph last year shares half of its words, or when it names a person or company last year's section did not. A deal reported again with a new amount is not new. Always check the filing. Open the proxy ↗ · Last year's proxy ↗
Sources
The related-party section (Item 404) of the latest annual proxy statement (DEF 14A), against last year's, compared by their words.
Also
CEO pay: the same proxy's pay versus performance table.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BRKR/export.csv") into a cell.